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Signal Peptide Prosequence 
RRTLOOsiaRR-\1clRNmslarRLsRsTYAS- - - - - - - - - - - - - - --- - - - • - - - - • 
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ANTI-MICROBIAL DEFENSIN-RELATED 
PEPTIDES AND METHODS OF USE 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
This application claims benefit of U.S. provisional patent 
application 60/846,030, filed Sep. 20, 2006, the complete 
contents of which are herein incorporated by reference. 
SEQUENCE LISTING 
This application includes as the Sequence Listing the com-
plete contents of the accompanying text file "Sequence.txt", 
created Sep. 18, 2007, containing 2,063 bytes, hereby incor-
porated by reference. 
DESCRIPTION 
Background of the Invention 
1. Field of the Invention 
The invention generally relates to antimicrobial peptides. 
In particular, the invention provides a novel defensin-related 
antimicrobial peptide and its analogs that are insensitive to 
physiological concentrations of salt and divalent cations. 
2. Background of the Invention 
The emergence of antibiotic resistant pathogens has 
become a world-wide health crisis and alternatives to tradi-
2 
which was named rattusin. The selection of the 31-amino acid 
peptide sequence which was synthesized was arbitrary, and 
the invention can be practiced with variants of the peptide 
sequence. Unlike defensins with a canonical six-cysteine 
5 motif, rattusin consists of five cysteines with a unique disul-
fide bonding pattern. Moreover, synthetic rattusin displayed 
potent, fast-killing activity against a range of Gram-negative 
and Gram-positive bacteria of clinical and agricultural impor-
tance, including antibiotic-resistant strains. Rattusin is thus 
10 clearly among the most potent defensins that have been 
reported. Importantly, rattusin retained its activity in the pres-
ence of physiological concentrations of salt and is thus the 
only defensin-related peptide whose activity is insensitive to 
salt. In further contrast to known defensins, rattusin also is 
15 insensitive to the presence ofMg2 +. Rattusin therefore repre-
sents an attractive drug candidate against systemic, antibi-
otic-resistant resistant infections. 
The invention provides substantially purified peptides hav-
ing an amino acid sequence represented by a sequence 
20 selected from the group consisting of: 
LRVRRTLQCSCRRVCRNTCSCIRLSRS TYAS (SEQ ID 
NO: 1); 
LQCSCRRVCRNTCSCIRLSRSTYAS (SEQ ID NO: 2); 
25 LRVRRTLQCSCRRVCRNTCSCI (SEQ ID NO: 3); 
LRVRRTLQCSCRRVCRNTCSCIRLSR (SEQ ID NO: 4); 
LQCSCRRVCRNTCSCI (SEQ ID NO: 5); and 
LRVRRTLQASARRVARNTASAIRLSRSTYAS (SEQ ID 
tional antibiotics are being sought. Antimicrobial peptides, 30 
essential components of the innate immune system, are 
capable of killing a broad spectrum ofbacteria through physi-
NO: 6) 
The invention further provides an antibacterial composi-
tion that is active under physiological conditions. The com-
position includes one or more peptides with an amino acid 
sequence represented by a sequence selected from the group 
consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, 
SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 6. In one 
embodiment of the invention, the salt concentration of the 
antimicrobial composition is in the range of from 0 to 250 
mM salt (and in one embodiment, is at least 50 mM), and the 
cal interaction and disruption of membranes. This antibacte-
rial property confers on these peptides an equal activity 
against both antibiotic-resistant and antibiotic-susceptible 35 
bacterial strains. Moreover, it is extremely difficult for bac-
teria to develop resistance to antimicrobial peptides. There-
fore, these peptides are actively being explored to treat bac-
terial infections, particularly those caused by antibiotic-
resistant strains. 40 salt is, for example, NaCl or KC!, or both. In another embodi-
ment of the invention, the divalent cation concentration of the 
antimicrobial composition is in the range of from Oto 5 mM, 
( and in one embodiment is at least 1 mM) and the divalent 
cation is, for example, Mg+2 or ca+2 , or both. 
Unfortunately, a majority of antimicrobial peptides discov-
ered to date show a significantly reduced antibacterial activity 
in the presence of physiological concentrations of salt and 
divalent cations. Therefore, the use of these peptides for the 
treatment of systemic bacterial infections, or for use in appli- 45 
cations that require exposure of the peptide to physiological 
concentrations of salt (e.g. during delivery of the peptide to a 
site of infection), is limited or ineffectual. 
The invention also provides a method for killing bacteria at 
a location having a salt concentration in the range of from Oto 
250 mM or a divalent cation concentration in the range of 
from Oto 5 mM. The method includes the step of exposing the 
bacteria to one or more peptides with an amino acid sequence There is an ongoing need to identify and develop agents 
with antibacterial activity, particularly agents that maintain 
their bactericidal activity under physiological conditions. 
SUMMARY OF THE INVENTION 
The present invention is based on the discovery of a novel, 
non-toxic antimicrobial peptide that maintains activity under 
physiological salt and divalent cation conditions. A genome-
wide computational screen of the entire rat genome led to 
identification of a peptide precursor related to defensins, 
which was denominated "Defa-rsl" (Patil et al., Physiol. 
Genomics, 20:1-11, 2004). However, no functional charac-
terization ofDefa-rsl was provided in that publication. Fur-
thermore, the mechanism by which biologically active, 
mature peptide is generated from defa-rel remains unknown, 
as does the identity of the native, mature peptide. 
This invention relates to a short 31-amino acid peptide, 
synthesized based on the C-terminal region of defa-rsl, 
50 represented by a sequence selected from the group consisting 
of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 
4, SEQ ID NO: 5, and SEQ ID NO: 6. The step of exposing 
kills the bacteria. In one embodiment of the invention, the 
bacteria are antibiotic-resistant bacteria. In another embodi-
55 ment of the invention, the location is in vivo. In yet another 
embodiment, the location is a circulatory, respiratory, diges-
tive, or reproductive system of a patient, and in another 
embodiment, the location is an open wound. 
The invention also provides a method for treating or pre-
60 venting a bacterial infection in a patient in need thereof. The 
method includes the steps of 1) providing to the patient a 
composition containing one or more peptides with an amino 
acid sequence represented by a sequence selected from the 
group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID 
65 NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 6, and 
2) allowing the peptides to contact bacteria under physiologi-
cal conditions in order to ameliorate or prevent the bacterial 
US 7,521,535 B2 
3 
infection. In one embodiment of the invention, provision of 
the composition is systemic, whereas in another embodiment, 
provision is topical. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1. Alignment ofrat defa-rsl with representative a-de-
fensins and related sequences. Dashes are created to maxi-
mize the alignment. Conserved amino acids are shaded. Rat-
tusin is a 31-amino acid, C-terminal peptide of defa-rsl as 10 
shown underlined. Known mature sequences of other 
defensins are also underlined. Note the difference in the cys-
teine pattern between defa-rsl with other a-defensins, 
despite a high conservation in the signal and pro-sequences. 
Abbreviations: rDefa6, rat a-defensin 6; RatNP-4, rat neu- 15 
trophil protein-4; DEFA5/HD-5, human a-defensin 5; CRS, 
cryptdin-related sequence. 
4 
measured with an alamarB!ue dye-based method. Data are 
representative of two independent experiments done in dupli-
cate. 
DETAILED DESCRIPTION OF THE PREFERRED 
EMBODIMENTS OF THE INVENTION 
The present invention provides a novel, potent and non-
toxic antimicrobial peptide that maintains activity under 
physiological salt and divalent cation conditions, and analogs 
thereof. The peptide, referred to herein as "rattusin", is thus 
suited for use in environments where physiological condi-
tions prevail, e.g. in vivo. This is in contrast to other known 
defensins which are salt and/or divalent cation sensitive and 
thus not suitable for use in vivo. The rattusin peptide dis-
played potent, fast-killing activity against a range of Gram-
negative and Gram-positive bacteria of clinical and agricul-
tural importance, including antibiotic-resistant strains. 
Rattusin is thus clearly among the most potent defensins that 
FIG. 2. Expression pattern of defa-rsl/rattusin mRNA in 
the rat gastrointestinal tract by RT-PCR. The housekeeping 
gene, GAPDH, was used to normalize template input. 
FIG. 3. RP-HPLC profiles of reduced and oxidized rat-
tusin. Reduced synthetic peptide was refolded by air oxida-
tion in 50 mM Tris buffer, pH 8.0, for 48 h. Oxidized rattusin 
was purified to homogeneity by RP-HPLC. Note that there is 
20 have been reported and represents an attractive drug candi-
date, especially against systemic, antibiotic-resistant infec-
tions. 
a decrease in the retention time of oxidized rattusin due to 25 
refolding. 
FIG. 4. Kinetics of killing of E. coli O157:H7 in the 
absence (A) and presence (B) of 100 mM NaCl by rattusin, 
cryptdin-4 and HD-5. E. coli 0157:H7 ATCC 700728 was 
incubated with 4 µM rattusin, cryptdin-4, HD-5, or an equal 30 
volume of 0.01 % acetic acid (no peptide) in duplicate in 25 
mM sodium phosphate buffer, pH 7 .4, 1 % TSB with and 
without 100 mM NaCl for 10, 30, 60, 120 and 240 min. 
Surviving bacteria were plated and counted. Data shown are 
means± SEM of two independent experiments. 35 
The rattusin peptides and derivatives and conservative vari-
ants thereof (i.e. analogs) are salt-insensitive, i.e. they retain 
their antibacterial activity even in the presence of physiologi-
cally relevant concentrations of salt. By "physiologically rel-
evant concentrations of salt" or "physiological salt concen-
trations" we mean the presence of NaCl or KC! (e.g. in 
biological fluids) from about 100 to about 200 mM. However, 
it should be understood that the peptides of the invention are 
also active at a wider range of salt concentrations e.g. from 
about O to about 250 mM. 
In addition, the peptides of the invention also retain their 
antibacterial activity in the presence of physiologically rel-
evant concentrations of divalent cations ( e.g. Mg2+ and/or 
Ca2+). By "physiologically relevant concentrations of diva-
lent cations" we mean the presence of Mg2+ and/or Ca2+ in 
biological fluids at concentrations ranging from about 1 mM 
to about 2 mM per divalent cation. However, it should be 
understood that the peptides of the invention are also active at 
a wider range of divalent cation concentrations, e.g. from 
about O mM to about 5 mM, per divalent cation. 
The primary amino acid sequence of rattusin is LRVR-
RTLQCSCRRVCRNTC SCIRLSRSTYAS (SEQ ID NO: 1 ). 
FIG. 5. Kinetics of killing of S. aureus in the absence (A) 
and presence (B) of 100 mM NaCl by rattusin, cryptdin-4 and 
HD-5. S. aureus ATCC 25923 was incubated with 2 µM 
rattusin, cryptdin-4, HD-5, or an equal volume of 0.01 % 
40 
acetic acid (no peptide) in duplicate in 25 mM sodium phos-
phate buffer, pH 7 .4, 1 % TSB with and without 100 mM NaCl 
for 10, 30, 60, 120 and 240 min. Surviving bacteria were 
plated and counted. Data shown are means ± SEM of two 
independent experiments. 
45 However, the amino acid sequence of the antibiotic peptide 
may be altered somewhat to produce variants, derivatives or 
analogs that are suitable for use in the present invention. For 
example, certain conservative amino acid substitutions may 
FIG. 6. Effect of salinity on the antibacterial activity of 
rattusin against S. aureus (A) and E. coli O157:H7 (B). S. 
aureus andE. coli were incubated with 2 and 4 µM of rattusin, 
or an equal volume of 0.01 % acetic acid (no peptide) in 25 
mM sodium phosphate buffer, pH 7.4, 1 % TSB with increas- 50 
ing concentrations of NaCl, for 4 h. Surviving bacteria were 
plated and counted. Data shown are means ± SEM of two 
independent experiments. 
FIG. 7. Effect of Mg2+ on the antibacterial activity of 
rattusin and cryptdin-4 against S. aureus (A) and E. coli 55 
O157:H7 (B). S. aureus or E. coli were incubated with rat-
tusin, cryptdin-4, or an equal volume of0.01 % acetic acid (no 
peptide) in 25 mM sodium phosphate buffer, containing 1 % 
TSB with 0, 1, 2 and 5 mM MgCl2 , pH 7.4, for 4 h. Surviving 
bacteria were plated and counted. Both peptides were used at 60 
identical concentrations for each bacterial strain (2 and 4 µM 
against S. aureus and E. coli, respectively). Data shown are 
means ± SEM of 2-3 independent experiments. 
FIG. 8. Absence of cytotoxicity of rattusin and cryptdin-4 
to Caco-2 cells. Cells were incubated with 100 µM of rattusin, 65 
cryptdin-4 or fowlicidin-1 for 24 h in DMEM with and with-
out 10% fetal bovine seruni for 24 hours. Cell viability was 
be made without having a deleterious effect on the ability of 
the peptide to function as an antibiotic, without destroying the 
salt and/or divalent cation tolerance of the peptide, and with-
out increasing toxicity, and in fact may lead to an increase in 
antibiotic activity and/or a decrease in toxicity. The resulting 
peptide may be referred to as a "conservative variant" or 
"conservative derivative" or "conservative analog". Those of 
skill in the art are familiar with the nature of such conservative 
substitutions, for example, substitution of a positively 
charged amino acid for another positively charged amino 
acid; substitution of a negatively charged amino acid for 
another negatively charged amino acid; substitution of a 
hydrophobic amino acid for another hydrophobic amino acid; 
substitution of an aliphatic amino acid for another aliphatic 
amino acid; etc. All such substitutions or alterations of the 
sequence of the peptide of the invention are intended to be 
encompassed by the present invention, so long as the resulting 
peptide is still bactericidal and resistant to the effects of 
physiological salt and/or divalent cation concentrations. In 
US 7,521,535 B2 
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"bactericidal" we mean that the peptides exhibit a minimum 
inhibitory concentration in the low micromolar concentration 
range ( < 10 µM) when measured by standard broth microdi-
lution assay as recommended by the Clinical and Laboratory 
general, such substituted sequences will be at least about 50% 
identical to the corresponding sequence in SEQ ID NO: 1, 
preferably about 60 to 70, or even 70 to 80, or 80 to 90% 
identical to SEQ ID NO: 1, and preferably about 95 to about 
100% identical. Those of skill in the art are well-acquainted 
with the calculation of identity between or among peptide 
sequences. 
In addition, certain other modifications ( e.g. chemical 
modifications) of the peptide are also contemplated. Such 
modifications may be referred to as variant or derivative or 
analog forms of the peptide. For example, the carboxyl ter-
minus of the peptide may be amidated; reactive groups may 
5 Standards Institute (CLSI). In addition, the peptides are non-
toxic or of low toxicity. By "non-toxic" and/or of "low tox-
icity", we mean that lysis of 50% of erythrocytes or killing of 
50% mammalian cells occurs at a concentration of> 100 µM 
peptide. Those of skill in the art will recognize that as long as 
10 the concentration of peptide that is required in order to be 
bactericidal is below the level of peptide that is toxic, the 
peptides may be useful as bactericides. 
The antimicrobial peptides of the invention may be used in 
a variety of ways. For example, they may be used as bacteri-
15 cidal agents to kill or damage unwanted bacteria. Suitable 
scenarios for such a use of the antimicrobial peptides include 
but are not limited to: treatment of established bacterial infec-
tions (for example, in bacterial hosts or potential bacterial 
be sulfonylated, lipidated, etc.; or L-amino acids of these 
sequences may be substituted with D-amino acids. Further, 
other variations of the sequences disclosed herein may also be 
carried out, e.g. the addition of a label or tag to the peptide to 
facilitate the isolation or detection of the peptides; removal or 
creation of a protease cleavage site; addition of charged or 
hydrophilic residues to promote solubility of the peptides; 
addition of specific residues to promote secondary structural 20 
elements ( e.g. to modulate helicity, amphipathicity, hydro-
phobicity, or cationicity); etc. 
In addition, the amino acid sequences of the peptides of the 
invention need not contain the precise number of residues as 
the exemplary optimized peptides disclosed herein. Certain 25 
deletions or additions may be tolerated (i.e. deletion or addi-
tion analogs), so long as the resulting peptide is bactericidal, 
of sufficiently low toxicity, and retains its insensitivity to 
physiological concentrations of salt and/or divalent cations. 
Especially, additions of other amino acid sequences at either 30 
the amino or carboxyl terminal (or both) are also encom-
passed herein, so long as such additions do not interfere with 
the activity and attributes of the rattusin peptide. Further, 
certain non-conservative amino acid substitutions may also 
be tolerated without compromising the efficacy or attributes 35 
of the peptide. Such non-conservative variants (analogs, 
derivatives) of rattusin will, in general, be at least about 50% 
identical to SEQ ID NO: 1, preferably about 60 to 70, or even 
70 to 80, or 80 to 90% identical to SEQ ID NO: 1, and also 
preferably about 95 to about 100% identical. Those of skill in 40 
the art are well-acquainted with the calculation of identity 
between or among peptide sequences. 
Further, even if the efficacy and/or attributes of rattusin are 
compromised or diminished somewhat in its analogs, they 
may still be useful. For example, a peptide that is less potent 45 
as an antibiotic may still be of much value if it has superior 
solubility or stability characteristics, or is less costly to manu-
facture, when compared to the parent molecule. In general, 
however, the antibiotic potency and/or divalent cation insen-
sitivity of the analog peptides will be at least about 50%, or 50 
preferably about 60%, or more preferably about 70-80%, and 
most preferably about 90% or more of that of the parent 
rattusin molecule. 
Chimeric polypeptides that contain more than one (i.e. 
multiple or a plurality of) antibiotic peptide sequence ( or 55 
variant, analog or derivative) within a polypeptide are also 
envisioned. The multiple peptides may be in tandem within a 
single, linear polypeptide chain, and may be separated, for 
example, by spacer peptides, many examples of which are 
known in the art. Alternatively, the structure of such a chimera 60 
may be branched, or a combination of linear and branched. 
The peptides that make up the chimera may be the same or 
different. Further, the chimera may be designed so that it is 
cleaved by proteases in vivo, releasing individual rattusin 
peptides. 65 
The peptide of the invention is "antimicrobial" or "antibi-
otic" or "bactericidal". By "antimicrobial" or "antibiotic" or 
hosts such as humans, other mammals, or any other living or 
non-living entity that is susceptible to bacterial infection or 
colonization); or prophylactically for the prevention of bac-
terial infections in such hosts ( e.g. the antimicrobial peptides 
may be administered to individuals whose immune systems 
are compromised and who may be susceptible bacterial infec-
tions); or administered topically to areas of a host that are 
susceptible to infection, e.g. to areas of the body that are likely 
sites for bacterial growth, e.g. the gums, open wounds, vagi-
nal and groin area, bed sores or areas which are likely to 
develop into bedsores, areas which are likely to be moist, e.g. 
under dressings, diapers, etc.); and the like. In particular, 
rattusin may be administered during treatment of a patient in 
conjunction with other antibiotics e.g. in order to prevent 
opportunistic infections caused by the overgrowth of normal 
or opportunistic flora that are not killed by the antibiotic, 
and/or to prevent the development of bacteria that are resis-
tant to the antibiotic. Alternatively, rattusin may be adminis-
tered instead of other antibiotics. Ratussin or its analogs may 
also be included in food preparations that might otherwise be 
susceptible to bacterial colonization, e.g. preserved goods 
that are susceptible to Clostridium botulinum. 
A wide variety of bacterial infections may be treated or 
prevented by administration of the antimicrobial peptide of 
the present invention. Examples of such bacteria include but 
are not limited to: coliform bacteria such as Escherichia coli; 
Salmonella species, e.g. S. typhimurium, S. enteritidis, andS. 
choleraesuis; Klebsiella species, e.g. K. pneumoniae, 
Pseudomonas species, e.g. P. aeruginosa; Listeria species 
e.g. L. monocytogenes; Staphylococcus species e.g. S. 
aureus, Mycobacterium species e.g. M. tuberculosis Entero-
coccus species, e.g. E.faecalis; Campylobacter species, e.g. 
C. jejuni, C. coli, and C. fetus; and Clostridium species, e.g. 
C. perfringens, C. difficile, C. tetani, and C. botulinum In 
particular, the peptides of the invention may be used to com-
bat bacteria that are resistant to conventional antibiotics, such 
as MRSA (methicillin-resistant Staphylococcus aureus), 
VRSA (Vancomycin-resistant S. aureus), VRE (Vancomy-
cin-Resistant Enterococcus ), Penicillin-Resistant Enterococ-
cus, PRSP (Penicillin-resistant Streptococcus pneumoniae), 
isoniazid/rifampin-resistant Mycobacterium tuberculosis 
and other antibiotic-resistant strains of E. coli, Salmonella, 
Campylobacter, and Streptococci. Such bacteria are herein 
referred to as "antibiotic-resistant" or "drug-resistant" or 
"multidrug-resistant", or by other similar terms that are well 
understood in the art. 
Several diseases or disease conditions that are associated 
with bacterial infections may be treated with the antibiotic 
peptides of the invention. Examples of such diseases or con-
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ditions include but are not limited to sepsis, pneumonia, cys-
tic fibrosis-associated chronic respiratory infections, inflam-
matory bowel diseases (particularly Crolm's disease), acne, 
and catheter-related infections, and others. In addition, the 
antibiotic peptides of the invention may be administered pro- 5 
phylactically to patients who are at risk for developing bac-
terial infections, e.g. those with compromised immune sys-
tems due to, for example, HIV infection, chemotherapy, etc., 
and those who have been treated with a course of traditional 
8 
administration is topical or orally or by injection. In addition, 
the compositions may be administered in conjunction with 
other treatment modalities such as substances that boost the 
immune system, various chemotherapeutic agents, other anti-
biotic agents, and the like. 
The present invention also provides a method of killing or 
damaging bacteria, particularly in environments where physi-
ological concentrations of salt and/or divalent cations prevail. 
In such environments, which include most in vivo applica-
antibiotics. 10 tions, other antimicrobial peptides cannot be used because 
their antibacterial activity is destroyed by the salt and/or 
divalent cations that are normally present in vivo. As 
described above, the antimicrobial peptide of the present 
invention does not suffer from such limitations. The method 
The present invention also provides new compositions for 
use in administration to patients (generally humans or mam-
mals). The compositions include a substantially purified anti-
microbial peptide as described herein, and a physiologically 
compatible carrier. In one embodiment of the invention, the 15 
composition in which the microbial peptide is contained com-
prises physiological levels of salt or divalent cations, or both. 
In other words, the salt concentration in the composition is in 
the range of 0-250 mM, and preferably is about 100 mM; 
and/or the divalent cation concentration in the composition is 20 
in the range of from about 0 mM to about 5 mM, and prefer-
ably is about 1 mM. Examples of salts that may be used in the 
preparation of such compositions include but are not limited 
to NaCl and KC!. Examples of sources of divalent cations 
include but are not limited to MgC12 , MgSO4 , CaC12 , MgSO4 , 25 
MnC12 , and MnSO4 , etc. In some embodiments, the only 
antimicrobial agent in the composition is the microbial pep-
tide of the present invention. However, in other embodiments 
other antimicrobial agents may also be present, i.e. a "cock-
tail" or mixture of two or more different antimicrobial agents 30 
(e.g. other antimicrobial peptides or traditional antibiotics) 
may be administered. 
The preparation of compositions for use as antimicrobial 
agents is well known to those of skill in the art. Typically, such 
compositions are prepared either as liquid solutions or sus- 35 
pensions; however solid forms such as tablets, pills, powders, 
pastes, ointments, suppositories, gelatinous compositions, 
and the like are also contemplated, as are aerosol forms. Solid 
forms suitable for solution in, or suspension in, liquids prior 
to administration may also be prepared. The preparation may 40 
also be emulsified, or incorporated into nanoparticles, micro-
particles, biodegradable polymers such as polylactide (PLA) 
and its copolymers with glycolide (PLGA), etc. The active 
ingredients may be mixed with excipients which are pharma-
ceutically acceptable and compatible with the active ingredi- 45 
ents. Suitable excipients are, for example, water, saline, dex-
trose, glycerol, ethanol and the like, or combinations thereof. 
In addition, the composition may contain minor amounts of 
auxiliary substances such as wetting or emulsifying agents, 
pH buffering agents, and the like. If it is desired to administer 50 
an oral form of the composition, various thickeners, flavor-
ings, diluents, emulsifiers, dispersing aids or binders and the 
like may be added. The composition of the present invention 
may contain any such additional ingredients so as to provide 
the composition in a form suitable for administration. The 55 
final amount of antimicrobial peptide in the formulations may 
vary. However, in general, the amount in the formulations will 
be from about 1-99%, weight/volume. 
The antimicrobial peptide compositions (preparations) of 
the present invention may be administered by any of the many 60 
suitable means which are well known to those of skill in the 
involves contacting the bacteria with the antimicrobial pep-
tides of the invention. In some instances, the bacteria will be 
killed outright, and signs or symptoms of bacterial coloniza-
tion or infection will be completely eradicated. However, 
those of skill in the art will recognize that much benefit can be 
derived even if all bacteria in a population are not killed 
outright. For example, in some cases, the ability of the bac-
teria to carry out metabolic reactions may be slowed or oth-
erwise attenuated by exposure to the antimicrobial peptides, 
or the reproductive potential of the bacteria may be decreased. 
All such lessening of the bacteria's ability to flourish in an 
environment in which they would typically establish colonies 
and persist may be of benefit to a host organism in need of 
treatment with the antimicrobial peptides of the invention. 
While in one embodiment of the invention, treatment of 
bacterial host organisms or potential bacterial host organisms 
is contemplated ( e.g. humans and other manimals, so that 
veterinary uses are also included), other uses of the antimi-
crobial peptides of the invention will also occur to those of 
skill in the art. For example, the treatment of surfaces for food 
preparation or of edible substances that might otherwise 
become colonized by bacteria; use in cleansing products such 
as soaps, detergents, lotions, etc.; for sterilization of drinking 
water; in packaging material; etc. 
EXAMPLES 
Example 1 
Characterization of Rattusin 
The emergence of antibiotic-resistant pathogens has 
become a major health crisis worldwide (1, 2). Novel antimi-
crobial drugs against resistant microbes are urgently needed. 
Defensins, an essential component of the innate immune 
system, are capable of killing a broad spectrum of bacteria 
through membrane permeabilization. These peptides initially 
interact with negatively charged phospholipids through elec-
trostatic interaction leading to subsequent cell membrane 
depolarization and disruption leading to cell death (3, 4 ). The 
physical mechanism of action ensures that they act on a broad 
spectrum of bacteria (including antibiotic-resistant strains), 
with an extremely low risk of developing resistance by bac-
teria. Therefore, defensins represent attractive antibacterial 
drug candidates particularly against resistant bacteria. 
Defensins are ubiquitously present in plants, fungi, insects, 
and vertebrate animals, including humans (3-8). In verte-
brates, defensins are characterized by the presence of mul-
tiple cysteines in well-defined spacing patterns. Based on the 
number and spacing pattern of cysteines, vertebrate defensins 
art, including but not limited to by injection, inhalation, 
orally, intravaginally, intranasally, by ingestion of a food or 
probiotic product containing the antimicrobial peptide, topi-
cally, as eye drops, via sprays, incorporated into dressings or 
bandages ( e.g. lyophilized forms may be included directly in 
the dressing), etc. In preferred embodiments, the mode of 
65 are further divided into six subfamilies. Besides well-de-
scribed a-, ~-, and 8-defensins with six characteristic cys-
teines (3, 4, 8-11 ), two groups of mouse-specific a-defensin-
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related sequences ( CRS 1 C and CRS4C) exist with 9 or 11 
cysteines (12-14). While ~-defensins are preferentially 
expressed in mucosa! epithelial cells lining mucosa! surfaces 
of the reproductive, digestive, and respiratory tracts, most a-
and 8-defensins as well as mouse CRSlC and CRS4C are 5 
produced in the granules of either phagocytes or Paneth cells, 
which are specialized cells lining the bottom of intestinal 
crypts (3, 4, 8-11 ). 
All defensins are strategically synthesized in precursor 
forms, and proteolytic processing is required to generate bio- 10 
logically active, mature peptides. Proteases responsible for 
the cleavage and activation of defensins have been identified 
in several cases. Trypsin is specifically involved in the pro-
teolysis of human defensin-5 (DEFA5/HD5) following an 
arginine residue (15), while matrix metalloproteinase 7 15 
(MMP-7 or matrilysin) prefers to cleave enteric mouse a-de-
fensins, known as cryptdins, after the serine residue (16, 17). 
10 
first-strand cDNA was used to amplify defa-rsl/rattusin and 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) with 
gene specific primers. The PCR product was analyzed by 
electrophoresis on 1.2% agarose gel containing 0.5 µg/ml 
ethidium bromide. The identity of rattusin PCR product was 
confirmed by cloning into a pGEM-T Easy vector (Promega, 
Madison, Wis.) followed by direct sequencing of a recombi-
nant plasmid. 
Peptide Synthesis 
Rattusin of 31 amino acids (LRVRRTLQCSCRRVCRN-
TCSCIRLSRSTYAS, SEQ ID NO: 1) was obtained from 
Bio-synthesis (Lewisville, Tex.), having been chemically 
synthesized in the reduced form using standard solid-phase 
synthesis and purified by reverse phase-high pressure liquid 
chromatography (RP-HPLC) to >95% purity. The mass of the 
peptide was confirmed by matrix assisted laser desorption 
ionization-time of flight (MALDI-TOF) mass spectrometry 
(MS) using Voyager DE-PRO (Applied Biosystems, Foster 
City, Calif.) housed in the recombinant DNA/protein core 
facility at Oklahoma State University. Recombinant cryptdin 
4, the most potent a-defensin in the mouse, was produced in 
bacteria as described (23, 24). HD-5 was chemically synthe-
sized as described (25). Cryptdin-4 and HD-5 were used as 
the reference peptides. 
Refolding of Synthetic Rattusin 
Synthetic rattusin in the reduced form at 0.1 mg/ml was 
exposed to 0 2 gas for 5 min in 50 mM Tris, pH 8.0, and stirred 
for 48 h at room temperature with the cap open as described 
Besides having direct microbicidal activities, AMPs have 
increasingly been appreciated to play a profound role in regu-
lating host immune responses to infections. Many peptides 20 
are shown to be actively involved in chemotaxis and activa-
tion of immune cells, regulation of dendritic cell differentia-
tion, induction of angiogenesis and re-epithelialization, and 
modulation of cytokine and chemokine gene expression (18-
20). However, the potential of defensins as therapeutics is 25 
dampened by a loss of the activity in the presence of physi-
ological concentrations of NaCl or divalent cations (such as 
Mg2+ and Ca2 +) (3, 8). Consequently, none of the defensin-
based therapeutics, except for a fungal defensin, plectasin 
(21), are under clinical development. 
We recently discovered a defensin-related peptide precur-
sor, namely defa-rsl, through a comprehensive genome-wide 
computational screen of the rat genome (22). Unlike 
defensins with a canonical six-cysteine motif, defa-rsl con-
sists of five cysteines with a unique disulfide bonding pattern 35 
(FIG. 1). However, neither the mechanism by which biologi-
cally active, mature peptide is generated from defa-rsl, nor 
the identity of the native, mature peptide is known. 
30 (14). Following air oxidation, refolded rattusin was purified 
by RP-HPLC on a 4.6x250 mm Vydac C18 column (Grace 
Vydac, Hesperia, Calif.) and BioLogic Duo Flow liquid chro-
matography system (Biorad, Hercules, Calif.). Buffer A con-
The following Example describes the synthesis and char-
acterization ofa 31 amino acid peptide, the sequence of which 40 
was selected arbitrarily based on the C-terminal region of 
defa-rsl. Functional analyses of the peptide (denominated 
rattusin) show that rattusin possesses potent antibacterial 
activity against Gram-positive and Gram-negative bacteria 
including antibiotic-resistant bacteria. More importantly, rat- 45 
tusin retains the antibacterial activity in serum or in the pres-
ence of high concentrations of salt and divalent cations. These 
properties make rattusin an attractive candidate for further 
therapeutic development. However, those of skill in the art 
will recognize that the sequence of rattusin is exemplary in 50 
nature, and that variants of this sequence may also be used in 
the practice of the invention. 
sisted of 5% acetonitrile & 0.18% trifluoroacetic acid (TFA) 
and Buffer B consisted of 90% acetonitrile & 0.15% TFA. 
The gradient used was O to 60% buffer B over 90 minutes at 
a flow rate of 1 ml/min. The eluted peptide was lyophilized 
and stored at -80° C. until use. 
Bacterial Culture and Antibacterial Assays 
All bacterial strains were purchased from either MicroBio-
logics (St. Cloud, Minn.) or ATCC (Manassas, Va.). Bacteria 
were grown in trypticase soy broth (TSB) overnight and sub-
cultured in the same broth for 3-4 hat 37° C. in a shaking 
incubator to the mid log phase. To study the antibacterial 
spectrum, a modified broth microdilution assay was used as 
described (26). Briefly, the mid log phase bacteria were 
washed with 25 mM sodium phosphate buffer, pH 7 .4, and 
suspended in 5% TSB in 25 mM sodium phosphate, pH 7 .4, 
to 5xl05 CFU/ml with and without 100 mM NaCl. Bacteria 
(90 µ!) were then dispensed in a 96-well plate, followed by 
addition of peptides (10 µ!) serially diluted in 0.01 % acetic 
acid. After overnight incubation at 37° C., the minimum 
inhibitory concentration (MIC) of each peptide was deter-
mined as the lowest concentration that gave no visible bacte-MATERIALS AND METHODS 
55 rial growth. 
RT-PCRAnalysis of the Gene Expression Pattern of defa-rsl/ 
Rattusin 
Different sequential segments of gastrointestinal tracts 
from stomach to colon were collected from 2 month old 
Sprague-Dawley rats. Total RNA was extracted using TRizol 
(Invitrogen, Carlsbad, Calif.). For each gastrointestinal seg-
ment RNA, 4 µg were reverse transcribed using random hex-
amers and SuperScript II reverse transcriptase and a first-
strand cDNA synthesis kit (Invitrogen, Carlsbad, Calif.) 
according to manufacturer's instruction. The subsequent 
PCR was carried out as described (22). Briefly, ¼oth of the 
To study the kinetics of bacterial killing, a standard colony 
counting assay was used as described (26). Rattusin and cryp-
tin-4 were incubated with 90 µI of 5xl05 CFU/ml Staphylo-
coccus aureus ATCC 25923 at the concentration of 2 µMeach 
60 orwithE. coli O157:H7 at the concentration of 4 µMeach in 
25 mM sodium phosphate buffer, pH 7 .4, with and without 
100 mM NaCl. The reaction was incubated at 37° C. for 10, 
30, 60, 120and240minanddilutedrapidlywithice-coldPBS 
and plated immediately. Plates were incubated at 37° C. for 
65 14-18 hours and viable bacteria were counted. 
The effect ofMg2+ on the antibacterial activity was studied 
by incubating rattusin and cryptdin-4 for 4 h with 90 µI of 
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5xl 05 CFU/ml Staphylococcus aureus at a concentration of 2 
µMeach or with E. coli O157:H7 at a concentration of 4 µM 
each in 1 % TSB, 25 mM sodium phosphate buffer, containing 
0, 1, 2 and 5 mM ofMgC12 , pH 7.4. 
12 
negative bacteria by a modified broth microdilution assay 
with and without 100 mM NaCl. As shown in Table 1, rattusin 
exhibited a broad spectrum of antibacterial activity with the 
MIC value in the range of 2-4 µM against most bacterial 
Cytotoxicity Assay 
Cytotoxicity against human Caucasian colon adenocarci-
noma (CACO-2) cell line (ATCC, Manassas, Va.) was mea-
sured using alamarB!ue dye (Biosource, Camarillo, Calif.) as 
described previously (26, 27). Briefly, CACO-2 cells were 
seeded into 96 well plate at 5xl04 in Dulbecco's modified 
Eagle's medium (DMEM) with 10% FBS and were grown 
overnight. The next day cells were washed once with DMEM 
followed by the addition of fresh DMEM with and without 
10% FBS and 100 µM of rattusin or cryptdin-4 or fowlicidin-
1. After 18 hours of incubation, alamarB!ue at 10% final 
amount was added to cells and cells were further incubated 
for 6 hours at 37° C. in a humidified 5% CO2 incubator. The 
plate was read with excitation at 545 nm and emission at 590 
nm. The percentage of cell death was calculated as [1-
(F peptide - F background)/ (F acetic acid F background)] x 100, where 
F peptide is the fluorescence of cells exposed to 100 µM peptide, 
F acetic acid is the fluorescence of cells exposed to 0.01 % 
acetic acid only, and F background is the background fluores-
cence of 10% alamarB!ue dye in cell culture medium without 
cells. 
5 strains tested. Rattusin was slightly more potent than the most 
potent mouse Paneth cell a-defensin, cryptdin 4 (9) in most 
cases. Furthermore, the antibacterial activity of rattusin 
remained largely unchanged in the presence of 100 mM 
NaCl, in sharp contrast to cryptdin-4, whose activity was 
10 dramatically diminished by salt. Importantly, rattusin also 
displayed a similar antibacterial efficiency against two strains 
of methicillin-resistant Staphylococcus aureus (MRSA) and 
multi-drug resistant Salmonella typhimurium DT 104 (Table 
1 ). 
Results 
Identification ofRattusin, a Novel Defensin-related Peptide 
The complete repertoires of the a-,~-, and 8-defensin gene 
families in a range of animal species have been identified by 
employing a comprehensive computational strategy (22, 28, 
29). Among over 100 novel defensins identified is a unique 
sequence in the rat, denominated "defa-rsl" (22). Defa-rsl 
shares a significant similarity with a-defensins in the signal 
and pro-sequences (22) (FIG. 1). However, unlike any clas-
sical a-defensins or mouse defensin-related peptides, defa-
rsl has five cysteines with a different spacing pattern in the 






To further analyze the detailed expression pattern of the 
40 
Defa-rsl gene, various intestinal segments were harvested 
across the longitudinal axis of 2-month old healthy rats, 
extracted for RNA, and subjected to RT-PCR analysis of 
Defa-rsl mRNAexpressionlevels.As shown in FIG. 2, Defa-
TABLE 1 
Antibacterial s12ectrurn of rattusin 
MIC(l!M) 
Rattusin C!J'.Qlidin-4 
ATCC 0mM l00mM 0mM l00mM 
Bacteria Number NaCl NaCl NaCl NaCl 
Gram-negative 
E.coli O157:H7 700728 2-4 2 8-16 >16 
S. typhimurium 14028 4 8 8 >16 
S. typhimurium 700408 4 4-8 4-8 >16 
DT104 
K. pneumoniae 13883 2-4 4-8 8 >16 
Gram-positive 
S. aureus 25923 4 4 4-8 "':16 
L. monocytogenes 19115 4 4 8 >16 
S. aureus 43300 4 4 2 8 
(MRSA) 
S. aureus BAA-39 4-8 4-8 >16 
(MRSA) 
To study the kinetics ofbacterial killing, one representative 
strain of Gram-negative and Gram-positive bacteria was used 
in a standard colony counting assay. Rattusin, cryptdin-4 and 
HD-5 at4 µMkilledE. coli by three logs within2 h(FIG. 4A). 
In the presence of 100 mM NaCl, killing of bacteria by 
rattusin was slightly delayed with a complete killing occur-
ring at 4 h. In contrast, Cryptdin-4 and HD-5 were completely 
inactivated in 100 mM NaCl (FIG. 4B). A similar trend also 
occurred with S. aureus. All three peptides at 2 µM killed S. 
aureus by two logs in 4 h (FIG. SA). Killing of S. aureus by 
rattusin was largely unaffected by 100 mM NaCl, whereas 
rsl mRNA was highly expressed in distal jejunum and the 
45 
entire ileum, but not in other parts of the gastrointestinal tract. 
Cryptdin-4 and HD-5, Paneth cell-specific a-defensins, also 
show a similar expression pattern in small intestine (30-32). 
This suggests that, similar to enteric a-defensins, Defa-rsl is 
likely to be produced by Paneth cells. 
50 cryptdin-4 and HD-5 were significantly inhibited in the pres-
ence of salt (FIG. SB). Collectively, these results clearly 
suggested that rattusin with a broad-spectrum, salt-insensi-
tive bactericidal activity is among the most potent defensins. 
To further study the effect of salinity, the antibacterial activity 
Antibacterial Properties ofRattusin 
To test whether defa-rsl is a putative defensin precursor 
and whether its carboxyl-terminal region is antibacterially 
active, we synthesized a 31-amino acid peptide containing 5 
cysteines, the sequence of which was selected based on the 
defa-rsl sequence. (The selection of the amino terminus of 
the peptide was arbitrary, in that the pattern of in vivo pro-
cessing of defa-rsl is unknown. Thus, other similar variant 
sequences may also display similar desirable characteristics.) 
This selected peptide was named rattusin (short for "rattus 60 
defensin"). Rattusin was synthesized in the reduced form and 
then further oxidized. Successful refolding was confirmed by 
RP-HPLC, showing a decrease in the retention time due to the 
formation of disulfide bonds and a change in the conforma-
tion (14, 33, 34) (FIG. 3). 
Refolded rattusin was then used to study its antibacterial 
activity against representative Gram-positive and Gram-
55 of rattusin was examined in the presence of increasing con-
centrations of NaCl. As shown in FIG. 6, rattusin maintained 
antibacterial activity against both E. coli and S. aureus in up 
to 200 mM NaCl. 
Divalent cations such as Mg2+ are usually present at 1 to 2 
mM in most biological fluids (20, 35). At such low concen-
trations, divalent cations are known to inhibit antibacterial 
activities of cationic peptides (36, 37). To study the effect of 
Mg2+ on the antibacterial activity, rattusin and cryptdin-4 
were incubated with bacteria in the presence of increasing 
65 concentrations ofMgC12 . There was a dose-dependent loss of 
the activity of cryptdin-4 against E. coli with complete inac-
tivation occurring at 2-5 mM ofMgC12 (FIG. 7 A). In contrast, 
US 7,521,535 B2 
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the activity of rattusin was largely unaffected in the presence 
ofMgCl2 (FIG. 7 A). Mg
2
+ did not inhibit the activity of either 
rattusin or cryptdin-4 against S. aureus (FIG. 7B). 
14 
insensitive to salt and divalent cations. The salt-insensitive 
activity of rattusin may be further exploited for the treatment 
of cystic fibrosis and Crohn's disease. Increased salt concen-
trations are believed to be responsible for inactivation of 
No Cytotoxicity of Rattusin 
The cytotoxic effect of rattusin to intestinal epithelial cells 
was studied using human Caco-2 cells. Fowlicidin-1 (100 
µM) was used as a positive reference since it showed signifi-
cant cytotoxicity towards mammalian cells (26). Following 
treatment of cells for 24 h, rattusin exhibited no cytotoxicity 
even at 100 µM, similar to cryptdin-4 (FIG. 8). 
5 defensins in the airway of the cystic fibrosis patients (47). In 
Crohn's disease, a deficiency of intestinal Paneth cell 
defensins is associated with an increase in susceptibility to 
bacterial infections ( 48). Therefore, exogenous delivery of 
potent, salt-insensitive rattusin represents a promising thera-
10 peutic strategy to treat both topical and systemic antibiotic-
resistant infections. 
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s ing its overall structure or forming patches of polar or hydro-
phobic pockets are mutated to change its conformation and/or 
amphipathicity. All peptide analogs are synthesized with and 
without incorporation of an amide group at the C-terminal 
10 end. Additional analogs are made based on the functional 
activities of these analogs. 
Example 2 
TABLE 2 
Rational Design of Rattusin Analogs 
15 Rational Design of Rattusin and Its Analogs 
Preliminary studies with rattusin revealed that the reduced 
peptide showed similar antibacterial efficacy to the refolded 
form in low concentrations of salt, but lost significant activi-
ties in high salt ( data not shown), suggesting that the presence 
of disulfide bonds and intact ~-sheet structure are critical in 
maintaining the salt-independent activity. Similar to several 
a- and ~-defensins ( 49-52), the central cysteine-rich motif of 
rattusin is flanked by long flexible N- and C-terminal tails, 
which are primarily composed of charged and uncharged 
polar residues (Table 2). The impact of N- and C-terminal 
tails and five cysteines of rattusin on its antibacterial, cyto-
toxic, chemotactic, and immuno-modulatory functions is 
investigated. 
Generation of Deletion Variants of Rattusin. 
The long N- and C-terminal tails are sequentially deleted to 
reveal their functional relevance (Table 2). Based on the 
results obtained, partial gradual deletions and substitutions of 
N- and C-terminal tail sequences are performed with the 
tail(s) that have a profound impact on the functions of rat-
tusin. 





To further confirm the impact of intact disulfide bonds on 
the antibacterial activity and to minimize the complications of 
possible peptide oxidation during incubation with bacteria, a 40 
linear variant with all five cysteines being replaced with ala-
nines is synthesized (Table 2). To pinpoint the relative sig-
nificance of each disulfide bond in maintaining salt-indepen-
dent antibacterial potency and the overall structure, 
<160> NUMBER OF SEQ ID NOS, 6 
<210> SEQ ID NO 1 
<211> LENGTH, 31 
<212 > TYPE, PRT 
<213> ORGANISM, Rattus sp. 
<400> SEQUENCE, 1 
SEQUENCE LISTING 
SEQ 
PEPTIDE SEQUENCE* ID NO, 
Rattusin LRVRRTLQ~S~RRV~RNT~S~IRLSRSTYAS 1 
RSNL\.N6 LQ~S~RRV~RNT~S~IRLSRSTYAS 2 
RSNL\.C9 LRVRRTLQ~S~RRV~RNT~S~I 3 
RSNL\.C5 LRVRRTLQ~S~RRV~RNT~S~IRLSR 4 
RSNL\.N6L\.C9 LQ~S~RRV~RNT~S~I 5 
RSN-Linear LRVRRTLQ~S~RRV~RNT~S~IRLSRSTYAS 6 
*Cysteines and replacement alanines shown in bold 
and underlined. 
While the invention has been described in terms of its 
preferred embodiments, those skilled in the art will recognize 
that the invention can be practiced with modification within 
the spirit and scope of the appended claims. Accordingly, the 
present invention should not be limited to the embodiments as 
described above, but should further include all modifications 
and equivalents thereof within the spirit and scope of the 
description provided herein. 
Leu Arg Val Arg Arg Thr Leu Gln Cys Ser Cys Arg Arg Val Cys Arg 
1 5 10 15 
Asn Thr Cys Ser Cys Ile Arg Leu Ser Arg Ser Thr Tyr Ala Ser 
20 25 30 
<210> SEQ ID NO 2 
<211> LENGTH, 25 
<212 > TYPE, PRT 
<213> ORGANISM, Rattus sp. 
US 7,521,535 B2 
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-continued 
<400> SEQUENCE, 2 
Leu Gln Cys Ser Cys Arg Arg Val Cys Arg Asn Thr Cys Ser Cys Ile 
1 5 10 15 
Arg Leu Ser Arg Ser Thr Tyr Ala Ser 
20 25 
<210> SEQ ID NO 3 
<211> LENGTH, 22 
<212> TYPE, PRT 
<213> ORGANISM, Rattus sp. 
<400> SEQUENCE, 3 
Leu Arg Val Arg Arg Thr Leu Gln Cys Ser Cys Arg Arg Val Cys Arg 
1 5 10 15 
Asn Thr Cys Ser Cys Ile 
20 
<210> SEQ ID NO 4 
<211> LENGTH, 26 
<212> TYPE, PRT 
<213> ORGANISM, Rattus sp. 
<400> SEQUENCE, 4 
Leu Arg Val Arg Arg Thr Leu Gln Cys Ser Cys Arg Arg Val Cys Arg 
1 5 10 15 
Asn Thr Cys Ser Cys Ile Arg Leu Ser Arg 
20 25 
<210> SEQ ID NO 5 
<211> LENGTH, 16 
<212> TYPE, PRT 
<213> ORGANISM, Rattus sp. 
<400> SEQUENCE, 5 
Leu Gln Cys Ser Cys Arg Arg Val Cys Arg Asn Thr Cys Ser Cys Ile 
1 5 10 15 
<210> SEQ ID NO 6 
<211> LENGTH, 31 
<212> TYPE, PRT 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic peptide based on ratussin sequence 
<400> SEQUENCE, 6 
Leu Arg Val Arg Arg Thr Leu Gln Ala Ser Ala Arg Arg Val 
1 5 10 
Asn Thr Ala Ser Ala Ile Arg Leu Ser Arg Ser Thr Tyr 
20 25 
We claim: 
1. A substantially purified peptide consisting of the amino 




2. A composition having antibacterial activity under physi-
ological conditions, comprising a peptide consisting of the 60 
amino acid sequence set forth in SEQ ID NO: 1. 
3. The antibacterial composition of claim 2, wherein said 
antimicrobial composition has a salt concentration in the 
range of from O to 250 mM salt. 
4. The antibacterial composition of claim 3, wherein said 




5. The antibacterial composition of claim 3, wherein said 
salt concentration is at least 50 mM. 
6. The antibacterial composition of claim 2, wherein said 
antimicrobial composition has a divalent cation concentra-
tion in the range of from O to 5 mM. 
7. The antibacterial of claim 6, wherein said divalent cation 
is Mg+2 or ca+2 , or both. 
8. The antibacterial composition of claim 6, wherein said 
divalent cation concentration is at least 1 mM. 
* * * * * 
